Division of Johnson & Johnson
Latest From Alza Corp.
Biotech will cut 46 staff, mostly in research, including the entire antibody group, to focus on commercializing its Phase III thrombocytopenia candidate fostamatinib. Rigel adds industry vet Eldon Mayer to head up commercial team.
US Inhaled CNS drug biotech Alexza looks set to be acquired by Spain’s Ferrer, the licensee of its only marketed product Adasuve outside of the US, in an all-cash offer that includes contingent value rights.
FDA’s “complete response” letter asks the company to reduce the rate of optical errors and improve the instructions for use of the patient-activated, hand-held analgesic system.
Partnering its PD-1-specific antibody candidate with three other companies, Merck indicates a new era may have arrived for testing novel agents in combination. Also, NIH partners with 10 biopharmas to transform the discovery model and Myriad moves to buy Crescendo.
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Johnson & Johnson
- Senior Management
Ernest Mario, PhD, Chmn. & CEO
Matthew K Fust, SVP, CFO
Daniel N Swisher, Jr., SVP, Sales & Mktg.
Howard Rosen, Pres.
- Contact Info
Phone: (650) 564-5000
1900 Charleston Rd.
P.O. Box 7210 Mountain View, CA 94039-7210
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.